Trazodone is one of the most widely prescribed sleep aids and antidepressants in the country, and it also happens to be one of the more well documented causes of a false positive drug screen. If a collector, an employer, or a donor has ever wondered why a routine urine screen flagged as positive for amphetamines or MDMA when nothing but a nightly trazodone tablet was in the picture, the answer sits in the drug's chemistry, not in any wrongdoing.
This is a pharmacology problem, not a cheating problem, and it has a known fix built into every properly run testing program: confirmation testing. Understanding how trazodone interacts with immunoassay screens helps collectors interpret non-negative results correctly and helps donors know exactly what to say when a Medical Review Officer calls.
What Trazodone Is and Why It Shows Up in Testing Conversations
Trazodone hydrochloride is FDA approved for major depressive disorder and is commonly prescribed off label at lower doses for insomnia. According to the FDA prescribing information, trazodone is extensively metabolized in the liver, and less than 1 percent of an oral dose is excreted unchanged. The label specifically identifies the pathway that matters here: in vitro studies show trazodone is metabolized via oxidative cleavage to an active metabolite called meta-chlorophenylpiperazine, or mCPP, through the CYP3A4 enzyme (FDA prescribing information for trazodone hydrochloride). That single metabolite is the whole story behind the false positive pattern seen in labs and collection sites.
mCPP is structurally similar enough to amphetamine-class compounds that it can bind to the antibodies used in certain immunoassay screens, tricking the assay into reading a signal it interprets as amphetamine, methamphetamine, or MDMA. This is called cross-reactivity, and it is a known limitation of antibody-based screening technology in general, not something unique or unusual to trazodone.
Dosing matters here too. The FDA prescribing information lists a typical starting dose of 150 mg per day in divided doses, with outpatient dosing usually capped at 400 mg per day. At those dose ranges, a meaningful share of the drug is routed through the CYP3A4 pathway toward mCPP production on an ongoing basis for as long as the prescription continues, which is why the interference shows up in people taking trazodone nightly for sleep just as often as in people taking it for depression at higher doses.
The Research Behind the Cross-Reactivity
Two peer-reviewed studies indexed in the National Library of Medicine's PubMed database laid this out clearly. A 2011 study in the Journal of Analytical Toxicology tested reference standards of mCPP alongside real patient urine samples that had been confirmed negative for amphetamine, methamphetamine, and MDMA by gas chromatography-mass spectrometry. The researchers found a strong correlation between mCPP concentration and a positive signal on the Amphetamines II immunoassay, and noted that at their institution, false positive amphetamine results tied to trazodone occurred often enough that at least 8 cases turned up in a single 26 day stretch (Baron et al., Journal of Analytical Toxicology, PubMed).
A second study, published the year before in the same journal, looked specifically at the EMIT II Ecstasy immunoassay used to screen for MDMA. The authors traced a series of patients whose urine screened positive for MDMA on the immunoassay but failed to confirm on liquid chromatography-tandem mass spectrometry. Follow up testing showed those patients were positive for trazodone and its mCPP metabolite, and independent testing of pure mCPP and trazodone standards confirmed significant cross-reactivity with the ecstasy assay (Logan et al., Journal of Analytical Toxicology, PubMed). In plain terms, a patient taking nothing but a prescribed sleep aid can screen presumptive positive for a party drug they never touched.
Which Immunoassay Panels Are Affected
Not every screening panel reacts the same way to mCPP, and not every trazodone user will trigger a false positive. Reactivity depends on dose, individual metabolism, urine concentration, and which manufacturer's immunoassay a lab or point of care device uses. The table below summarizes what the published research has documented so far.
| Immunoassay screen | Substance class flagged | What the research found |
|---|---|---|
| Amphetamines II (Roche Diagnostics) | Amphetamine / methamphetamine | Strong correlation between mCPP concentration and a positive immunoassay signal, confirmed with reference standards and real patient samples |
| EMIT II Ecstasy assay | MDMA | Trazodone and mCPP produced significant cross-reactivity; presumptive positives did not confirm by LC-MS/MS |
| GC-MS or LC-MS/MS confirmation | Amphetamine, methamphetamine, MDMA | Confirmatory methods correctly distinguish mCPP and trazodone from the actual target drugs, resolving the false positive |
Why a Presumptive Positive Is Never the Final Word
This is exactly the scenario that mandatory confirmation testing exists to catch. Immunoassay screens are built for speed and low cost, and their tradeoff is a wider net that occasionally catches a structurally similar compound like mCPP. Federal workplace drug testing regulations under 42 CFR Part 82 require that any non-negative screen be confirmed by a second, chemically distinct analytical method, such as gas chromatography-mass spectrometry or liquid chromatography-tandem mass spectrometry, before a result can ever be reported as positive (49 CFR Part 40, section 40.87). Confirmation testing separates compounds by their exact mass and structure rather than by antibody binding, so mCPP and trazodone show up as exactly what they are instead of being mistaken for amphetamine or MDMA. A well designed collection and screening program, built around reliable drug testing supplies and a clear confirmation protocol, is what keeps a chemistry quirk from turning into an unfair outcome for a donor.
What a Donor Should Tell the Medical Review Officer
SAMHSA's Mandatory Guidelines establish the Medical Review Officer role specifically to review non-negative laboratory results and rule out legitimate medical explanations before a result is ever verified as positive to an employer (SAMHSA, Frequently Asked Questions About Federal Workplace Drug Testing). Anyone contacted after a non-negative screen should be direct and specific:
- Name the exact medication, trazodone or trazodone hydrochloride, along with the dose and how long it has been taken.
- Bring or reference the prescription, pharmacy label, or prescriber contact information if asked.
- Mention it even if the screen flagged as amphetamine or MDMA rather than something that sounds related to trazodone. The mCPP connection is not obvious from the panel name alone, so it is worth stating outright.
- Let the confirmation result speak for itself. A verified negative on GC-MS or LC-MS/MS after a trazodone related presumptive positive is a well established outcome, not an exception.
Collectors and program administrators benefit from knowing this pattern too. A related overview of common medications that can cause a false positive on drug tests and a closer look at how the Medical Review Officer review process works both cover the surrounding procedure in more depth.
What This Means for Testing Programs
None of this means amphetamine or MDMA panels are unreliable. It means immunoassay screening was never designed to be the final answer, only the first filter. Immunoassays remain valuable precisely because they are fast, inexpensive, and sensitive enough to catch a wide range of substances in a single pass, and that same sensitivity is what occasionally picks up a structurally similar compound like mCPP. Programs that skip confirmation testing on non-negative results, or that report a screen result directly to an employer without MRO review, are the ones that create real problems for donors on legitimate prescriptions. Programs that follow the two step process, screen, then confirm, then MRO review, catch cases like trazodone's mCPP interference exactly the way the system is built to.
This is also why collection sites and clinics should never treat a non-negative point of care result as a final determination on its own, regardless of how confident the color change or line on a cup looks. The result is presumptive by design. Sending every non-negative specimen to a laboratory for confirmatory testing, and routing every confirmed positive through MRO review before it reaches an employer, is what keeps a known chemistry quirk like this one from turning into a wrongful accusation.
Frequently asked questions
Can trazodone cause a false positive for amphetamines?
Yes. Published research shows trazodone's metabolite mCPP cross-reacts with the Amphetamines II immunoassay, producing a presumptive positive signal in some patients taking the medication as prescribed.
Can trazodone cause a false positive for MDMA or ecstasy?
Yes. A separate study found trazodone and mCPP cross-react with the EMIT II Ecstasy immunoassay, and patients on trazodone who screened positive for MDMA did not confirm positive on chemically specific follow up testing.
Does everyone who takes trazodone test positive on a screen?
No. Cross-reactivity depends on dose, individual metabolism, and how concentrated the urine sample is, along with which immunoassay a lab or collection site uses. Many trazodone users never trigger a non-negative screen at all.
How does confirmation testing resolve a trazodone related false positive?
Confirmation methods like gas chromatography-mass spectrometry or liquid chromatography-tandem mass spectrometry identify a compound by its exact structure rather than by antibody binding, so they correctly separate mCPP and trazodone from actual amphetamine or MDMA.
What should someone say to the Medical Review Officer after a non-negative result?
State the exact medication name, trazodone hydrochloride, along with dose and duration, and be prepared to provide the prescription or prescriber information. The Medical Review Officer reviews this before any result is verified as positive.
This article is general information, not medical or legal advice. Testing programs should rely on their Medical Review Officer and laboratory toxicologist for interpretation of any individual result, and individuals should talk to their prescribing clinician about any medication questions.
